Did Supernus Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SUPN
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
Yahoo Finance5d
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN). The branded pharmaceutical industry relies on a high-cost, high-reward business model ...
Business Insider5d
Lost Money on Supernus Pharmaceuticals, Inc.(SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals ...
pharmaphorum1d
Supernus bulks up its Parkinson's portfolio with Adamas takeover
Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.
kalkinemedia6d
Is Supernus Pharmaceuticals (NASDAQ:SUPN) Seeing Increased Institutional Activity?
Highlights,Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals, reflecting growing institutional activity.,Several financial firms, including Janney Montgomery Scott LLC and ...
The Pharma Letter6d
Supernus Pharmaceuticals
Supernus' neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients ...
Benzinga.com3d
Supernus Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SUPN | Benzinga
Explore Supernus Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SUPN. Supernus' SPN-820 Phase 2b study in treatment-resistant depression ...